Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Ads
Novo Nordisk is suing Eli Lilly over ads for its weight-loss and anti-diabetes treatments. The company claims the ads are misleading and use outdated trial data.
Novo Nordisk, the maker of Ozempic, filed a lawsuit against Eli Lilly on Tuesday. The Danish pharmaceutical company alleges that Eli Lilly's ads for its weight-loss and anti-diabetes treatments, Zepbound and Mounjaro, are false and misleading. According to Novo Nordisk, Eli Lilly used outdated trial data to make its drugs appear more effective.
The complaint centers on Eli Lilly's comparison of its highest doses to lower doses of Novo Nordisk's medicines. Novo Nordisk claims that Eli Lilly intentionally selected outdated studies to make this comparison.
Eli Lilly's ads are for its weight-loss and anti-diabetes treatments, which compete with Novo Nordisk's products. Novo Nordisk's lawsuit aims to stop Eli Lilly from running these ads, which it believes are misleading to consumers.
Go Deeper
What is Ozempic used for?
Ozempic is used to treat type 2 diabetes and has also been prescribed for weight loss. It is made by Novo Nordisk, a Danish pharmaceutical company.
What are Zepbound and Mounjaro?
Zepbound and Mounjaro are weight-loss and anti-diabetes treatments made by Eli Lilly, a US pharmaceutical company. They compete with Novo Nordisk's products in the market.
Why is Novo Nordisk suing Eli Lilly?
Novo Nordisk is suing Eli Lilly over ads for its weight-loss and anti-diabetes treatments. The company claims that the ads are false and misleading, and that Eli Lilly used outdated trial data to make its drugs appear more effective.
What is the main issue with Eli Lilly's ads?
The main issue is that Eli Lilly compared its highest doses to lower doses of Novo Nordisk's medicines, using outdated trial data. Novo Nordisk claims that this comparison is misleading and intentionally selected to favor Eli Lilly's products.
What does Novo Nordisk want to achieve with the lawsuit?
Novo Nordisk wants to stop Eli Lilly from running the ads, which it believes are misleading to consumers. The company aims to prevent Eli Lilly from continuing to use what it considers to be false and misleading advertising.
More us
usHouse Republicans pass procedural vote on legislative agenda
House Republicans have passed a procedural vote on their legislative agenda, with a final vote expected later. Independent Rep. Kevin Kiley of Califor
Jul 21
usTrump Defends 50% Tariffs on Canadian Goods
The US has announced 50% tariffs on most Canadian goods, set to take effect next month. President Trump defended the move, stating Canada needs the US
Jul 21
usDefense Secretary Testifies on Iran War Costs and Funding Needs
The US Defense Secretary testified before the Senate, stating that the war with Iran has cost $37.5 billion so far and that additional funding is need
Jul 21